GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
11 oct. 2023 09h05 HE
|
GRI Bio, Inc.
- Live moderated webcast with Marc Hertz, Chief Executive Officer of GRI Bio on Tuesday, October 24th at 11:00 AM ET LA JOLLA, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:...
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
05 oct. 2023 08h45 HE
|
GRI Bio, Inc.
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s...
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 09h05 HE
|
GRI Bio, Inc.
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
23 août 2023 09h00 HE
|
GRI Bio, Inc.
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation...
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 08h05 HE
|
GRI Bio, Inc.
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment...
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
07 août 2023 08h35 HE
|
GRI Bio, Inc.
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
GRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference
03 août 2023 08h30 HE
|
GRI Bio, Inc.
- Live moderated webcast fireside chat today, August 3rd at 11:15 AM ET LA JOLLA, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
24 juil. 2023 09h00 HE
|
GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...
GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series
05 juil. 2023 08h45 HE
|
GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM ET LA JOLLA, CA, July 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
27 juin 2023 08h45 HE
|
GRI Bio, Inc.
- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...